Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.
Discover
Related topics
Intoducing spheroOne: Automated sorting and isolation of single spheroids and organoids
Jun 21, 2022
spheroONE is an innovative single large-particle sorter and dispenser which revolutionizes 3D cellular models handling....
Outstanding post-sort sample recovery on the WOLF Cell Sorter
Jun 14, 2022
The new WOLF G2 instrument has significantly expanded the capabilities of gentle benchtop microfluidic cell sorting...
Incucyte AI module: Advanced Label-Free Classification Analysis
Jun 6, 2022
Monitor adherent cell morphology changes objectively to determine live/dead cell counts or classify cells based on...
Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters
Jun 3, 2022
Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine...
Intoducing cellenONE: The revolutionary Single Cell isolator
May 25, 2022
A revolutionary platform based on sciDROP PICO precision dispensing technology and coupled with advanced image...
Advances in Leukemia research using shear flow and Bioflux system
May 24, 2022
Leukemia is a rare cancer with many subtypes. The production of abnormal leukocytes create disruptions in the immune...
May 4, 2022
A prodigy incorporating a unique combination of patent-pending innovative technologies that takes flow cytometry to the...
In-vivo webinar: a versatile use of SPECT/CT in the development of theranostic tracers
Mar 9, 2022
Combining (preclinical) imaging and targeted therapy, is the basis of theranostics. In this webinar, Dr. Florea will...
Introducing IsoPlexis Single-Cell Natural Killer Panel
Mar 4, 2022
Because of their ability to kill tumour cells, NK cells are an attractive target in cancer immunotherapy, therapeutic...
Enhanced small particle detection on CytekAurora and Northern Lights
Mar 2, 2022
Aurora system with ESP option, can fully resolve particles around 70nm and from the 80nm PS bead. The new violet laser...
Nov 1, 2016
Psoriasis is a chronic inflammatory disease affecting 1–3 % of the general population. Traditional systemic therapies for psoriasis, such as methotrexate, have a potential for long-term toxicity and may not always provide sufficient improvement of the condition.
In a recent study by van der Fits et al. a mouse model of dermatitis closely resembling human psoriasis was obtained by the topical application of Imiquimod (IMQ) to mouse ear skin. IMQ, linked to the IL-23/IL-17 axis, can function as a toll-like receptor 7/8 (TLR7/8) ligand and initiate a potent innate immune system response. Mouse skin lesions showed increased epidermal proliferation, abnormal differentiation of keratinocytes, epidermal accumulation of neutrophils in micro-abcesses, neo-angiogenesis, and infiltrates consisting of CD4(+) T cells, CD11c(+) dendritic cells, and plasmacytoid dendritic cells.
In the mouse dermatitis study presented here, in vivo phagocyte-mediated myeloperoxydase (MPO) activity was monitored non-invasively by detecting bioluminescent signal resulting from MPO-specific luminol catabolism. MPOluminol bioluminescence signal is known to be co-localized with histological sites of inflammation as well as infiltration of neutrophils and activated eosinophils.
Related technologies: Fluorescence, luminescence, X-ray, radiographic imaging
Brand profile
Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.
More info at:
www.bruker.com/